VAXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VAXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vaxxinity has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
1. Financial Strength : 0/10Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Vaxxinity might have Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Vaxxinity (OTCPK:VAXX) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score | Performance Potential and All-in-One Screener Examples (1) |
91 - 100 | Highest outperformance potential |
81 - 90 | Good outperformance potential |
71 - 80 | Likely to have average performance |
51 - 70 | Poor future performance potential |
0 - 50 | Worst future performance potential, or not enough data |
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Thank you for viewing the detailed overview of Vaxxinity's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumita Ray | officer: Chief Legal Officer, Secretary | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Prime Movers Lab Fund I Lp | 10 percent owner | P.O. BOX 12829, JACKSON WY 83002 |
Landon E Ogilvie | director | 505 ODYSSEY WAY, EXPLORATION PARK FL 32953 |
Katherine A. Eade | director | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
James Alan Smith | director | 505 ODYSSEY WAY, EXPLORATION PARK FL 32953 |
Gabrielle B Toledano | director | 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065 |
Lou Reese | director, officer: Executive Chairman | C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201 |
Mei Mei Hu | director, 10 percent owner, officer: See Remarks | C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201 |
United Biomedical Inc | 10 percent owner | 25 DAVIDS DR, HAUPPAUGE NY 11788 |
Dakin Sloss | 10 percent owner | 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022 |
Peter Powchik | director | REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591 |
Jason Pesile | officer: See Remarks | C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201 |
George R Hornig | director | 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017 |
James Chui | director | C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201 |
Peter Diamandis | director | 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292 |
From GuruFocus
By Stock market mentor Stock market mentor • 02-02-2023
By Marketwired • 08-29-2023
By PurpleRose PurpleRose • 08-11-2022
By PurpleRose PurpleRose • 08-01-2022
By Marketwired • 06-22-2023
By PurpleRose PurpleRose • 08-04-2022
By sperokesalga sperokesalga • 03-21-2023
By Ds*** Ds*** • 09-01-2022
By Marketwired • 08-10-2023
By PurpleRose PurpleRose • 07-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.